Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rocky Mountain Cancer Center
Denver, Colorado, United States
- Florida Cancer Specialists
Fort Myers, Florida, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Florida Cancer Specialists - North
St. Petersburg, Florida, United States
- Ingalls Cancer Research Center
Harvey, Illinois, United States
- Research Medical Center
Kansas City, Missouri, United States
- Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
- Spartanburg Regional Medical Center/gibbs Cancer Center
Spartanburg, South Carolina, United States
- Tennessee Oncology Pllc
Nashville, Tennessee, United States
- Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Jul 2015
- Primary completion
- 15 May 2021
- Completion
- 15 May 2021
- Last update posted
- 5 Dec 2023
- Registered enrollment
- 62
- Registry id
- NCT02318784
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.